CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale.
CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide.
The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership.
Strategic Partnerships Powering the Summit
CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi government partners shaping the Kingdom's mobility future: Royal Commission for Riyadh City (RCRC), Riyadh Municipality, Ministry of Transport & Logistic Services (MoTLS), Riyadh Public Transport, Ministry of Municipalities and Housing (MoMH), Ministry of Communications and Information Technology (MCIT), Digital Government Authority (DGA), and Transport General Authority (TGA).
The event features keynote addresses from H.E. Fahd bin Abdulmohsan Al Rasheed, Chairman of SCEGA and Head of the Saudi Arabian Delegation to the Urban 20, and H.E. Dr. Rumaih Al Rumaih, Vice Minister of Transport & Logistic Services and Acting President of TGA and private sector leaders like Mate Rimac of Croatia’s Rimac Automobili; Bill Russo, Founder & CEO, Automobility Ltd.; Dr. James Yu, Chairman and CEO, QCraft; Chris Li, Co-founder and CFO, Neolix; Jinjun Tian, CEO, Geely Auto Middle East; Valerie Labi, CEO & Co-Founder, Wahu Mobility; and Yvonne Aki-Sawyerr, Mayor, Freetown, South Africa and Chair, C40.
Leading private-sector mobility partners – Uber, door2door, Budget Saudi Arabia, and Changan Almajdouie – are supporting the event with advanced transport services and EV solutions, demonstrating the Kingdom's accelerating shift toward cleaner, more connected mobility systems.
Climate Leadership Through The Bridge Initiative
CoMotion GLOBAL 2025 is fully climate-offset through The Bridge Initiative, which supports high-integrity climate action across the Global South. The initiative measures event emissions, selects high-quality carbon credits, and retires them to certify the summit's climate contribution.
For this year's event, The Bridge Initiative selected a major waste-to-energy project in Bogotá, Colombia, that captures methane from one of Latin America's largest landfills and converts it into renewable electricity and biomethane. The project reduces roughly 800,000 tons of CO₂e annually – equivalent to removing 400,000 cars from the road. Certified by CerCarbono, it delivers environmental impact and social benefits, improving air quality for nearby low-income communities while ensuring transparency in climate action.
A Dynamic Agenda Shaping Mobility's Future
CoMotion GLOBAL 2025 features a two-stage program, dedicated Mobility Labs, the inaugural CoMotion Urban Visionary Distinction, and the launch of Mayors in Motion – a global network for city leaders to exchange insights, coordinate strategies, and champion practical solutions.
Key themes include the Kingdom's emergence as a first-wave deployment market for autonomous technologies, exclusive insights into Riyadh's groundbreaking 176-km metro megaproject, and the rapid growth of EV manufacturing, adoption, and infrastructure. The summit will also explore how Expo 2030 and the 2034 World Cup can drive long-term mobility upgrades.
Global spotlights will highlight Africa's shared-mobility breakthroughs, Latin America's electrification leadership, China's mobility playbook, and AI-driven logistics advances from North America and Europe, and the advent of Sentient Cities in the Middle East and internationally.
"CoMotion GLOBAL is where the world's urban mobility future takes shape, and the energy in Riyadh today is extraordinary," said John Rossant, Founder and CEO of CoMotion GLOBAL. "From ministers to mayors to the world's most inventive technologists, the conversation is clear: the next decade of mobility transformation will be shaped at the city level. Riyadh is the perfect host for that dialogue – bold, ambitious, and redefining what a future-ready city can be."
About CoMotion
CoMotion is the world’s leading platform where the most influential leaders, companies, startups, and policymakers meet to shape the future of mobility. With flagship events in Riyadh, Los Angeles, and Miami, CoMotion fosters meaningful dialogue and catalyzes investments that advance sustainable and equitable transportation worldwide.
For more information, visit www.comotionglobal.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251207218971/en/
Contacts
Media Contact:
Kristin Ford-Glencross
comotion@antennagroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom